<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34426623</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1<sup>G93A</sup> and TDP-43<sup>Q331K</sup> transgenic mouse models of ALS.</ArticleTitle><Pagination><StartPage>17027</StartPage><MedlinePgn>17027</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17027</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-96418-0</ELocationID><Abstract><AbstractText>GLP-1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective effects in cellular and animal models of Alzheimer's disease (AD) and Parkinson's disease (PD). There are currently few studies investigating GLP-1 receptor agonists in the treatment of ALS, where these neuroprotective effects may be beneficial. Here we investigate the effects of liraglutide, a GLP-1 receptor agonist, in two well characterised transgenic mouse models of ALS (SOD1<sup>G93A</sup> and TDP-43<sup>Q331K</sup>) to determine if liraglutide could be a potential treatment in ALS patients. Doses of liraglutide previously shown to have efficacy in AD and PD mouse models were used. Behavioural testing was carried out to ascertain the effect of liraglutide on disease progression. Immunohistochemical analysis of tissue was used to determine any neuroprotective effects on the CNS. We found that liraglutide dosed animals showed no significant differences in disease progression when compared to vehicle dosed animals in either the SOD1<sup>G93A</sup> or TDP-43<sup>Q331K</sup> mouse models of ALS. We also observed no changes in motor neuron counts or glial activation in lumbar spinal cords of liraglutide treated mice compared to vehicle dosed mice. Overall, we found no evidence to support clinical evaluation of liraglutide as a potential candidate for the treatment of ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keerie</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown-Wright</LastName><ForeName>Heledd</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkland</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grierson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alix</LastName><ForeName>James J P</ForeName><Initials>JJP</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holscher</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Second Hospital, Neurology Department, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, School of Medicine, University of Sheffield, Sheffield, UK. r.j.mead@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SITRAN/APR13/983-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SITRAN/JUL16/987-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491049">Aif1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>839I73S42A</RegistryNumber><NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069450" MajorTopicYN="N">Liraglutide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008159" MajorTopicYN="N">Lumbar Vertebrae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34426623</ArticleId><ArticleId IdType="pmc">PMC8382676</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-96418-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-96418-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>H&#xf6;lscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Acta Physiol. Sin. 2014;66(5):497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">25331995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong, J.L.Y., de Pablo-Fernandez, E., Foltynie, T., Noyce, A.J. The association between type 2 diabetes mellitus and Parkinson&#x2019;s disease. J. Parkinsons Dis. Preprint(Preprint), 1&#x2013;15 (2020).</Citation></Reference><Reference><Citation>H&#xf6;lscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer&#x2019;s and Parkinson&#x2019;s disease models. Neuropharmacology. 2018;136:251&#x2013;259. doi: 10.1016/j.neuropharm.2018.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.01.040</ArticleId><ArticleId IdType="pubmed">29402504</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG, et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson&#x2019;s disease. Acta Neuropathol. 1994;87(4):343&#x2013;348. doi: 10.1007/BF00313602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313602</ArticleId><ArticleId IdType="pubmed">8017169</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer&#x2019;s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012;122(4):1316&#x2013;1338. doi: 10.1172/JCI59903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI59903</ArticleId><ArticleId IdType="pmc">PMC3314463</ArticleId><ArticleId IdType="pubmed">22476197</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney AM, Griffin RJ, Timmons S, O&#x2019;Connor R, Ravid R, O&#x2019;Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer&#x2019;s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging. 2010;31(2):224&#x2013;243. doi: 10.1016/j.neurobiolaging.2008.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.04.002</ArticleId><ArticleId IdType="pubmed">18479783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Lee JKW, Lee CTC. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J. Neurol. 2019;266(9):2233&#x2013;2243. doi: 10.1007/s00415-019-09405-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09405-x</ArticleId><ArticleId IdType="pubmed">31152300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: Sources, localization and functions. Molecular Neurobiol. 2013;47:145&#x2013;171. doi: 10.1007/s12035-012-8339-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8339-9</ArticleId><ArticleId IdType="pubmed">22956272</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e37885. doi: 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008;9(1):4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11(1&#x2013;2):38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Molecular Neurosci. 2002;18(1):7&#x2013;14. doi: 10.1385/JMN:18:1-2:07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:18:1-2:07</ArticleId><ArticleId IdType="pubmed">11931352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter K, H&#xf6;lscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13(1):4&#x2013;9. doi: 10.1186/1471-2202-13-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-13-33</ArticleId><ArticleId IdType="pmc">PMC3352246</ArticleId><ArticleId IdType="pubmed">22443187</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-Smith CM, Manning S, McClean PL, Coakley MF, O&#x2019;Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-&#x3b2; plaque and glial pathology in a mouse model of alzheimer&#x2019;s disease. NeuroMolecular Med. 2013;15(1):102&#x2013;114. doi: 10.1007/s12017-012-8199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-012-8199-5</ArticleId><ArticleId IdType="pubmed">23011726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcclean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2011;31(17):6587&#x2013;6594. doi: 10.1523/JNEUROSCI.0529-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0529-11.2011</ArticleId><ArticleId IdType="pmc">PMC6622662</ArticleId><ArticleId IdType="pubmed">21525299</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean PL, Jalewa J, H&#xf6;lscher C. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav. Brain Res. 2015;5(293):96&#x2013;106. doi: 10.1016/j.bbr.2015.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2015.07.024</ArticleId><ArticleId IdType="pubmed">26205827</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt B, Holscher C. P4&#x2013;420: Liraglutide, a drug developed to treat type 2 diabetes, has protective effects in mouse models of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2011;7(4):e59&#x2013;e59. doi: 10.1016/j.jalz.2011.09.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.09.116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gejl M, Gjedde A, Egefjord L, M&#xef;ller A, Hansen SB, Vang K, et al. Alzheimer&#x2019;s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:1&#x2013;10. doi: 10.3389/fnagi.2016.00108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00108</ArticleId><ArticleId IdType="pmc">PMC4877513</ArticleId><ArticleId IdType="pubmed">27252647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Jalewa J, Sharma M, Li G, Li L, H&#xf6;lscher C. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson&#x2019;s disease. Neuroscience. 2015;1(303):42&#x2013;50. doi: 10.1016/j.neuroscience.2015.06.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.06.054</ArticleId><ArticleId IdType="pubmed">26141845</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Knippenberg S, Thau N, Ragancokova D, K&#xf6;rner S, Huang D, et al. Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol. Neurobiol. 2013;33(3):347&#x2013;357. doi: 10.1007/s10571-012-9900-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-012-9900-9</ArticleId><ArticleId IdType="pubmed">23271639</ArticleId></ArticleIdList></Reference><Reference><Citation>Knippenberg S, Thau N, Dengler R, Brinker T, Petri S. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of als. PLoS ONE. 2012;7(6):e36857. doi: 10.1371/journal.pone.0036857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036857</ArticleId><ArticleId IdType="pmc">PMC3380029</ArticleId><ArticleId IdType="pubmed">22745655</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE. 2012;7(2):e32008. doi: 10.1371/journal.pone.0032008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032008</ArticleId><ArticleId IdType="pmc">PMC3285661</ArticleId><ArticleId IdType="pubmed">22384126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, Bennett EJ, Kennerley AJ, Sharp P, Sunyach C, Kasher P, et al. Optimised and rapid pre-clinical screening in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) PLoS ONE. 2011;6(8):1&#x2013;12. doi: 10.1371/journal.pone.0023244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023244</ArticleId><ArticleId IdType="pmc">PMC3158065</ArticleId><ArticleId IdType="pubmed">21876739</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling S-C, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. 2013;110(8):E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson, J., Alix, J., Kennerley, A., Shaw, P., Mead, R., Stephenson, J., et al. A huTDP-43Q331K mouse model shows signs of both motor neuron disease (MND) and frontotemporal dementia (FTD). Vol. 5, F1000Research. (2016).</Citation></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127&#x2013;1138. doi: 10.1016/S1474-4422(14)70129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Zabolotny JM, Huang H, Lee H, Kim YB. Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. Molecular Metabolism. 2016;5:589&#x2013;601. doi: 10.1016/j.molmet.2016.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2016.06.011</ArticleId><ArticleId IdType="pmc">PMC5021669</ArticleId><ArticleId IdType="pubmed">27656397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y, et al. The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci. Rep. 2016;6(1):1&#x2013;11. doi: 10.1038/s41598-016-0001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-016-0001-8</ArticleId><ArticleId IdType="pmc">PMC4886514</ArticleId><ArticleId IdType="pubmed">27240461</ArticleId></ArticleIdList></Reference><Reference><Citation>Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, et al. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J. Alzheimer&#x2019;s Dis. 2015;47(3):715&#x2013;728. doi: 10.3233/JAD-150307.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150307</ArticleId><ArticleId IdType="pmc">PMC6080853</ArticleId><ArticleId IdType="pubmed">26401706</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, Lorenzini I, Barrameda D, O&#x2019;Conner AG, Barrows JM, Starr A, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019;1:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciervo Y, Gatto N, Allen C, Grierson A, Ferraiuolo L, Mead RJ, et al. Adipose-derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS. Mol. Ther. Methods Clin. Dev. 2021;11(21):413&#x2013;433. doi: 10.1016/j.omtm.2021.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2021.03.017</ArticleId><ArticleId IdType="pmc">PMC8044387</ArticleId><ArticleId IdType="pubmed">33869658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciervo Y, Ning K, Jun X, Shaw PJ, Mead RJ. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. Mol. Neurodegener. 2017;12(1):85. doi: 10.1186/s13024-017-0227-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0227-3</ArticleId><ArticleId IdType="pmc">PMC5683324</ArticleId><ArticleId IdType="pubmed">29132389</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean PL, Gault VA, Harriott P, H&#xf6;lscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer&#x2019;s disease. Eur. J. Pharmacol. 2010;630(1&#x2013;3):158&#x2013;162. doi: 10.1016/j.ejphar.2009.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2009.12.023</ArticleId><ArticleId IdType="pubmed">20035739</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XH, Li L, H&#xf6;lscher C, Pan YF, Chen XR, Qi JS. Val8-glucagon-like peptide-1 protects against A&#x3b2;1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience. 2010;170(4):1239&#x2013;1248. doi: 10.1016/j.neuroscience.2010.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.08.028</ArticleId><ArticleId IdType="pubmed">20727946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The arrive guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412. doi: 10.1371/journal.pbio.1000412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000412</ArticleId><ArticleId IdType="pmc">PMC2893951</ArticleId><ArticleId IdType="pubmed">20613859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson Laboratory. Protocol 27057 - Tg(Prnp-TARDBP*)Dwc [Internet]. [cited 2020 Jun 18]. Available from: https://www.jax.org/Protocol?stockNumber=017933&amp;protocolID=27057</Citation></Reference><Reference><Citation>Healy S, McMahon J, Owens P, Dockery P, FitzGerald U. Threshold-based segmentation of fluorescent and chromogenic images of microglia, astrocytes and oligodendrocytes in FIJI. J. Neurosci. Methods. 2018;1(295):87&#x2013;103. doi: 10.1016/j.jneumeth.2017.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2017.12.002</ArticleId><ArticleId IdType="pubmed">29221640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>